Sitagliptin With Pembro in RCC and Melanoma

This study is testing whether adding the drug sitagliptin to the standard immunotherapy pembrolizumab is safe and may help people with advanced melanoma or advanced renal cell carcinoma (kidney cancer) whose cancer has stopped responding to prior PD-1 or PD-L1 immunotherapy. The study has two parts. In the first part, small groups of participants will receive different doses of sitagliptin along with a fixed dose of pembrolizumab. This helps researchers find the highest dose of sitagliptin that can be given safely. In the second part, more participants will receive the safest dose to see how

Trial Details

NCT ID
NCT07634380
Phase
PHASE1
Sponsor
Fernando Maciel Barbosa
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Sitagliptin
  • Pembrolizumab
Locations (sample)
  • Iowa City, Iowa, United States|41.66113,-91.53017

Key Eligibility Criteria

  • Histologically and/or cytologically confirmed unresectable metastatic renal cell carcinoma with clear cell component with no neuroendocrine differe…
  • Has received at least 2 doses of an approved anti-PD-1/PD-L1 mAb
  • Has demonstrated disease progression after anti-PD-1/PD-L1 mAb as defined by RECIST v1.1. The initial evidence of disease progression (PD) is confi…
  • Progressive disease has been documented within 12 weeks from last dose of anti-PD-1/PD-L1 mAb (refractory disease) or ≥12 weeks from last dose of a…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →